NCT05240976: Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia
- State
- Under way
- Phase
- Phase 2
- People
- 80 planned
- Started
- 23 Feb 2022
- Primary completion
- Feb 2027
- Arms
- NMDAE plus Anti-inflammatory Agent (AIFA)
- Results
- None posted
- 15 Feb 2022: Trial registered
- 23 Feb 2022: Trial started